esomeprazole / Generic mfg. - LARVOL DELTA

Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan. (PubMed, Drug Healthc Patient Saf) - "Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

REAL-WORLD RISK OF DRUG-INDUCED TUBULOINTERSTITIAL NEPHRITIS (ISN-WCN 2026) - "As shown in Figure 1a, 11 such drugs were identified: omeprazole, ibuprofen, pantoprazole, ciprofloxacin, pembrolizumab, nivolumab, vancomycin, carboplatin, pemetrexed, tacrolimus, and esomeprazole.The relationship between TIN and these suspected drugs is illustrated in the volcano plot (Figure 1a). Individuals aged over 60 years, male, or those who have taken 9 specific drugs including omeprazole are at a higher risk of developing DITIN. The findings of this study can provide important information for the early identification of drug-related acute interstitial nephritis and lay a foundation for future research on the pathogenesis of DITIN."

Clinical • Real-world • Real-world evidence • Immunology • Infectious Disease • Nephrology • Respiratory Diseases • Tuberculosis

The effect of individual sulfasalazine administration and in combination with esomeprazole on buccal mucosa of albino rats: histological, immunohistochemical, and molecular study. (PubMed, Odontology) - "SFZN individually has significantly increased keratin thickness, disrupted Nrf2 machinery and glutathione tissue level, while SFZN in combination with ESOm showed significant increase in area% of iron deposition. DNA degradation using comet assay was evaluated using Kruskal-Wallis and Dunn's test which revealed no significant difference of tail length and tail moment in SFZN group and ESOm group but these parameters were significantly different in these two groups in relation to the control group (p < 0.05)."

Journal • Preclinical • Immunology • Renal Disease

ESUS-ESD: Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: LanZhou University | Initiation date: Jan 2026 ➔ Apr 2026

Trial initiation date • Gastric Cancer • Gastroenterology • Oncology • Peptic Ulcer • Solid Tumor

Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in critically ill patients: a randomized, double-blind, non-inferiority phase 3 trial. (PubMed, Ann Intensive Care) - "Adverse events were similar between groups, but Ilaprazole had a significantly lower incidence of hepatobiliary disorders (0.9% vs. 5%, p = 0.012). Ilaprazole demonstrated non-inferiority to esomeprazole in preventing UGI bleeding in critically ill patients at high risk of stress ulcer."

Clinical • Head-to-Head • Journal • P3 data • Gastroenterology • Gastrointestinal Disorder • Hepatology • Inflammation • Pneumonia • Stress Ulcer

Genetic causal association between kidney stones and proton pump inhibitors. (PubMed, Int Urol Nephrol) - "In conclusion, this study found no evidence supporting a causal role for PPIs in increasing kidney stone risk, providing genetic-level evidence to support the safe use of PPIs in patients with gastric ulcers or gastroesophageal reflux disease."

Journal • Chronic Kidney Disease • Gastroenterology • Gastroesophageal Reflux Disease • Metabolic Disorders • Nephrology • Peptic Ulcer • Renal Calculi • Renal Disease • ATP4A

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (clinicaltrials.gov) - P4 | N=594 | Recruiting | Sponsor: Chinese University of Hong Kong | Trial completion date: Jan 2026 ➔ Jul 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Gastroenterology • Peptic Ulcer

Drug-Induced Thrombocytopenia from Proton Pump Inhibitors and H₂ Blockers: A Systematic Review and Comparative Analysis of Published Case Reports (THSNA 2026) - "Representative PPI reports (pantoprazole, lansoprazole, omeprazole/esomeprazole) and classical H₂RA reports (cimetidine, ranitidine, famotidine) were abstracted for onset (days), recovery (days), bleeding and ICU status. Case-level evidence indicates both PPIs and H₂RAs can cause abrupt, reversible thrombocytopenia with onset within days and recovery within 1–2 weeks; PPI reports show a trend toward earlier onset and higher bleeding documentation. Findings are limited by reporting bias and small numbers; prospective pharmacovigilance and mechanistic testing are needed to confirm class-specific risks. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Case report • Clinical • Review • Hematological Disorders • Thrombocytopenia

EUROHELICAN-The First Helicobacter Pylori Screen-and-Treat Population-Based Study in Young Adults in Europe. (PubMed, United European Gastroenterol J) - P | "H. pylori screening and-treat program in 30-34 age group in Slovenia is feasible; H. pylori treatment is very effective with acceptable rate of AEs. Different approaches to raising public awareness are needed to increase participation rates."

Journal • Gastric Cancer • Infectious Disease • Oncology • Solid Tumor

Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Network Meta-analysis. (PubMed, J Neurogastroenterol Motil) - "Nineteen studies evaluating 5 P-CABs (vonoprazan, tegoprazan, keverprazan, fexuprazan, and zastaprazan) and 2 PPIs (lansoprazole and esomeprazole) were included. P-CABs, especially vonoprazan, showed superior efficacy compared to PPIs in both the initial and maintenance treatment of EE. These findings support the use of P-CABs as a potent and reliable first-line option for EE management, particularly in high-risk populations, with acceptable safety outcomes."

Clinical • Journal • Retrospective data • Review • Gastrointestinal Disorder

A Study to Assess the Effect of Acid-Reducing Medicines on ATH434 in Healthy Volunteers (ANZCTR) - P1 | N=12 | Not yet recruiting | Sponsor: Alterity Therapeutics Limited

New P1 trial • CNS Disorders • Movement Disorders • Multiple System Atrophy

Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience. (PubMed, Allergol Immunopathol (Madr)) - "Skin testing is a valuable tool in predicting hypersensitivity reactions associated with PPIs. Although rare, hypersensitivity reactions may occur in patients with negative skin tests."

Journal • Retrospective data • Allergy • Immunology

Safety and Efficacy of Esomeprazole-Containing Regimens for Helicobacter pylori Eradication: A Multicenter Retrospective Study. (PubMed, Dig Dis) - "Esomeprazole-containing regimens are effective and well tolerated for H. pylori eradication. Bismuth- and doxycycline-based quadruple therapies achieved the highest eradication rates, particularly in treatment-naïve patients. Tailored strategies incorporating bismuth or quadruple therapy may benefit patients with prior treatment failures or from lower socioeconomic backgrounds. Further research should consider regional resistance patterns and prospective designs."

Journal • Retrospective data • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Solid Tumor

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (clinicaltrials.gov) - P=N/A | N=414 | Recruiting | Sponsor: Asian Institute of Gastroenterology, India | Initiation date: Jun 2025 ➔ Dec 2025

Trial initiation date • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials. (PubMed, EClinicalMedicine) - "At 8 weeks, zastaprazan 20 mg, vonoprazan 20 mg, and esomeprazole 40 mg demonstrated moderate-certainty superiority over rabeprazole 20 mg and omeprazole 20 mg with RDs ranging from 0.05 to 0.11, while only vonoprazan 20 mg demonstrated moderate-certainty benefit versus lansoprazole 30 mg (RD: 0.04)...Vonoprazan 20 mg and rabeprazole-ER 50 mg demonstrated moderate-certainty benefit compared with pantoprazole 40 mg (RDs: 0.12 and 0.09, respectively).At 24 weeks, vonoprazan 10 mg and 20 mg showed moderate-to-high-certainty benefit versus lansoprazole 15 mg (RDs: -0.11 and -0.13, respectively), while in direct comparisons, esomeprazole 20 mg outperformed lansoprazole 15 mg and pantoprazole 20 mg, with approximately 40-50% relative reductions in recurrence...Comparative trials evaluating newer P-CABs against optimized PPI strategies, including twice-daily dosing, are needed to evaluate efficacy and long-term safety, particularly with respect to hypergastrinemia and infection..."

Journal • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

The two-hit hypothesis in acute esophageal necrosis: black esophagus in severe atherosclerosis and untreated gastroesophageal reflux disease: a case report. (PubMed, J Med Case Rep) - "This case highlights an atypical, nonbleeding presentation of acute esophageal necrosis and reinforces the importance of maintaining clinical suspicion even in the absence of classic symptoms. It underscores the relevance of the "two-hit" hypothesis, where ischemic insult and impaired mucosal defense act synergistically to cause esophageal necrosis. Timely endoscopic evaluation and early initiation of appropriate therapy led to favorable outcomes in this high-risk patient. Increased awareness of such presentations can aid in earlier diagnosis and reduce the high morbidity and mortality associated with acute esophageal necrosis."

Journal • Atherosclerosis • Candidiasis • Cardiovascular • Coronary Artery Disease • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease • Pain • Peptic Ulcer

Increased Risk of Ischemic Events in Patients With Stroke Treated With Clopidogrel and a P-CAB or PPI. (PubMed, Stroke) - "Among PPIs, esomeprazole was associated with a higher risk of major adverse cardiovascular events (HR, 1.46 [95% CI, 1.10-1.92]) and stroke recurrence (HR, 1.50 [95% CI, 1.13-2.00]). Concomitant use of P-CABs or PPIs with clopidogrel was associated with an increased risk of ischemic events in patients with stroke. P-CABs or PPIs should, therefore, be prescribed cautiously for patients with stroke treated with clopidogrel."

Journal • Cardiovascular • Gastroenterology • Ischemic stroke • Myocardial Infarction

ARV-102-105: A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the Single-Dose Pharmacokinetics of ARV-102 in Healthy Participants. (clinicaltrialsregister.eu) - P1 | N=24 | Completed | Sponsor: Arvinas Operations Inc.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia (clinicaltrialsregister.eu) - P4 | N=128 | Not yet recruiting | Sponsor: Landspitali

Head-to-Head • New P4 trial • Dyspepsia

Effects of Proton Pump Inhibitors on Remodeling and Fibrosis in Eosinophilic Esophagitis. (PubMed, J Allergy Clin Immunol) - "PPIs modulate remodeling/fibrosis-related gene expression in patients with EoE and inhibit TGF-β‒induced profibrotic responses in HEFs, supporting antifibrotic potential that may help limit fibrostenotic progression in EoE."

Journal • Eosinophilic Esophagitis • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • TGFB1

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study. (PubMed, Drug Metab Pers Ther) - "Findings from this preliminary study indicate a higher frequency of NMs and RMs compared to IMs and PMs in this PPI-resistant cohort with GORD. Most resistance was observed to the second-generation PPI esomeprazole. A limitation was the lack of a control group comprising PPI-sensitive patients."

Journal • Observational data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • CYP2C19

Aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) complicated with acute pancreatitis: A case report. (PubMed, Medicine (Baltimore)) - "This case suggests that AQP4-IgG-mediated immune damage may not be confined to the CNS. There may be a possible association between NMOSD and AP in the pathophysiological mechanisms. AP may be a rare extra-CNS complication of NMOSD. Our case expands the spectrum of potential systemic complications in NMOSD, highlighting the need for increased clinical vigilance."

Journal • CNS Disorders • Immunology • Neuromyelitis Optica Spectrum Disorder • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Pancreatitis • Rare Diseases

Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, J Clin Med) - " Fexuprazan 40 mg may provide similar efficacy compared to esomeprazole 40 mg in EE, with a comparable safety profile to esomeprazole in EE and LPRD patients. However, the evidence is highly uncertain, requiring further studies."

Journal • Retrospective data • Review • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (clinicaltrials.gov) - P=N/A | N=4824 | Not yet recruiting | Sponsor: Fudan University | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • Gastric Cancer • Infectious Disease • Oncology • Solid Tumor

Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Asian Institute of Gastroenterology, India

New trial • Stress Ulcer